Article Figures & Data
Tables
Generic name Brand name Dosing Half-life Indication GLP-1 RAs Short-acting GLP-1 RA Exenatide Byetta (Eli Lilly) 5–10 μg SQ twice daily 2.4 h Glycemic control in adults with T2DM Lixisenatide Adlyxin (Sanofi) 10–20 μg SQ daily 3 h Diabetes management in conjunction with insulin Liraglutide Victoza (Novo Nordisk) 0.6–1.8 mg SQ daily 13 h Glycemic control in T2DM Liraglutide Saxenda (Novo Nordisk) 0.6–3 mg SQ daily 13 h Weight loss and chronic weight management Long-acting GLP-1 RA Dulaglutide Trulicity (Eli Lilly) 0.75–4.5 mg SQ weekly 5 d Improvement of blood sugar in T2DM Semaglutide Rybelsus (Novo Nordisk) 3–14 mg orally daily 7 d Treatment of T2DM, an oral agent Semaglutide Ozempic 0.25 to 2 mg SQ weekly 7 d Diabetes management; off label for weight management Semaglutide Wegovy 0.25–2.4 mg SQ weekly 7 d Approved by Food and Drug Administration for chronic weight management Exenatide long-acting release Bydureon Bcise (AstraZeneca) 2 mg SQ weekly 2 wk Glycemic control in adults with T2DM Dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs Tirzepatide Mounjaro 2.5–15 mg SQ weekly 5 d Treatment for T2DM; off label for weight loss Tirzepatide Zepbound (Eli Lilly) 5–15 mg SQ weekly 5 d Treatment for obesity SQ = subcutaneously; T2DM = type 2 diabetes mellitus.
